The group of fast-acting compounds that are used to induce complete sedation are known as intravenous anesthetics. Propofol, etomidate, ketamine, and barbiturates are the most commonly used intravenous anesthetics. Ketamine is used in the emergency medicine cases, owing to its strong dissociative, sympathomimetic, and analgesic effects. Propofol is the standard drug for induction of anesthesia and etomidate is most commonly used in the cases of hemodynamic instability. While, barbiturate helps to reduce intracranial pressure and it is useful for patients with high head trauma or intracranial pressure.
In addition, anaesthesiologists prefer to use injectable anaesthetics, as they work faster compared to other anaesthetics. IV (Intravenous) anesthetics are typically small and highly lipophilic molecules and being lipophilic, helps to facilitate their rapid preferential distribution into brain and spinal cord, as both the organ are highly vascularized and lipophilic.
India intravenous anaesthetic market growth is attributed to the increasing number of different surgical procedures that depend on IV anaesthesia. For instance, according to Obesity Surgery Society of India data, the weight loss surgeries performed in India are continuously increasing. In 2014, around 8 bariatric surgeries were performed in India and it reached around 20,242 in 2018. Moreover, in India the number of bariatric surgeons increased from 8 to 250 during 2004 to 2018.
The healthcare spending in India is continuously increasing over the time. For instance, according to the India Brand Equity Foundation (IBEF) data, India’s healthcare industry is expected to reach around US$ 372 Bn by 2022. The increasing investments in healthcare facilities is expected to boost demand for intravenous anaesthetics. For instance, in 2019, according to the National Investment Promotion and Facilitation Agency of India revealed some data of upcoming hospital projects in the country, in which, around US$ 243.74 million are setting up for the 500 number of bed multispecialty hospital in Dharamshala, India. Similarly, in Mumbai, around US$ 96.52 Mn was expected to invest for super-speciality hospital.
Key features of the study:
- This report provides in-depth analysis of the market, India intravenous anesthetic market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period 2019-2027, considering 2018 as the base year
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the India intravenous anesthetic market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, key developments, and strategies
- Key players covered as a part of this study include Fresenius Kabi, AbbVie Inc., Baxter International Inc., B. Braun Melsungen AG, Maruishi Pharmaceutical Co., Ltd, Piramal Healthcare, Hikma Pharmaceuticals, and Mylan N.V.
- Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to future product launches, governmental initiatives, market expansions, and marketing tactics
- The India intravenous anesthetic market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers of reprocessed medical devices, research and consulting firms, new entrants, and financial analysts.
- India Intravenous Anesthetic Market, By Type:
- India Intravenous Anesthetic Market, By End User:
- Company Profiles
- AstraZeneca Plc*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Fresenius Kabi
- AbbVie Inc.
- Baxter International Inc.
- Braun Melsungen AG
- Maruishi Pharmaceutical Co.,Ltd
- Piramal Healthcare
- Hikma Pharmaceuticals
- Mylan N.V.
“*” marked represents similar segmentation in other categories in the respective section.